Changes of platelet function in Alzheimer-like triple transgenic mice and its mechanism
CSTR:
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [14]
  • | | | |
  • Comments
    Abstract:

    Objective To investigate the changes of the platelet function in APP/PS-1/tau(3xTg) mice, a murine model for Alzheimer's disease,and explore its mechanisms. Methods We assessed the change of function of platelet in 3xTg-AD mice by flow cytometry. Adhesion assay and Western blotting were used to compare with the data of wild type mice. Results Platelets from aged 3xTg-AD mice were normal in number and glycoprotein expression (P> 0.05), but adhere more avidly on matrices such as fibrinogen, compared with the platelets from age-matching wild type mice (P<0.05). The washed platelets of 3xTg-AD mice were adherent to fibrinogen, and also showed increased phosphorylation of selected signaling proteins, including PI3 kinase effector Akt and p38MAP kinase (P<0.05). In contrast, activation induced by several agonists in 3xTg-AD mice was similar to that of wild type platelets (P>0.05). Conclusions These results demonstrate that Alzheimer's mutations result in a significant hyper-activated adhesion state of circulating platelets, evident with the progression of the disease.

    Reference
    [1] Yamada M. Cerebral amyloid angiopathy: emerging concepts [J]. J Stroke, 2015, 17(1): 17-30.
    [2] Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease [J]. Neurology, 2007, 69(19): 1850-1858.
    [3] Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly [J]. Ann Neurol, 2011, 70(6): 871-880.
    [4] Canobbio I, Abubaker A A, Visconte C, et al. Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease [J]. Front Cell Neurosci, 2015, 9(65): 1-15.
    [5] Veitinger M, Varga B, Guterres SB, et al. Platelets, a reliable source for peripheral Alzheimer's disease biomarkers?[J]. Acta Neuropathol Comm, 2014, 2(1): 1-15.
    [6] Laske C. Clinical and biomarker changes in Alzheimer's disease [J]. New Engl J Med, 2012, 367(21): 2051-2052.
    [7] Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease [J]. Cell Signal, 2014, 26(9): 2040-2050.
    [8] Plagg B, Marksteiner J, Kniewallner KM, et al. Platelet dysfunction in hypercholesterolemia mice, two Alzheimer's disease mouse models and in human patients with Alzheimer's disease [J]. Biogerontology, 2015, 16(4): 1-16.
    [9] Mervis RF, Mckeon J, Pindell T, et al. A new paradigm for the treatment of Alzheimer's disease: targeting vascular activation[J]. J Alzheimers Dis, 2014, 40(3): 619-630.
    [10] Stellos K, Panagiota V, Kögel A, et al. Predictive value of platelet activation for the rate of cognitive decline in Alzheimer's disease patients [J]. J Cerebral Blood Flow & Metab, 2010, 30(11): 1817-1820.
    [11] Jarre A, Gowert NS, Donner L, et al. Pre-activated blood platelets and a pro-thrombotic phenotype in APP23 mice modeling Alzheimer's disease [J]. Cell Signal, 2014, 26(9): 2040-2050.
    [12] Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction [J]. Neuron, 2003, 39(3): 409-421.
    [13] Jackson SP, Nesbitt WS, Westein E. Dynamics of platelet thrombus formation [J]. J Thromb Haemost J, 2009, 7 Suppl 1(Supplement s1): 17-20.
    [14] Gowert NS, Donner L, Chatterjee M, et al. Blood platelets in the progression of Alzheimer's disease [J]. Plos One, 2013, 9(2): e90523.
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:2523
  • PDF: 2497
  • HTML: 0
  • Cited by: 0
History
  • Revised:November 26,2016
  • Online: July 08,2017
Article QR Code